Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma

Dermatology Research and Practice - Egypt
doi 10.1155/2012/259170
Full Text
Abstract

Available in full text

Categories
Dermatology
Date
Authors
Publisher

Hindawi Limited

Related search

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

PLoS ONE
Multidisciplinary
2015English

Malignant Melanoma Metastatic to the Larynx: Treatment and Functional Outcome

Current Oncology
Oncology
2010English

Beyond BRAF: Where Next for Melanoma Therapy?

British Journal of Cancer
Cancer ResearchOncology
2014English

Targeting Epigenetics for Treatment of BRAF Mutated Metastatic Melanoma With Decitabine in Combination With Vemurafenib: A Phase Lb Study

Oncotarget
Oncology
2017English

Targeting Metastatic Melanoma

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2008English

Metastatic Malignant Melanoma of the Gastric Mucosa

Internal Medicine
Internal MedicineMedicine
2010English

An Update on BRAF Inhibitors and Other New Molecular Targets for the Treatment of Malignant Melanoma of the Skin

Clinical Medicine Insights: Dermatology
2013English

Melatonin Synergizes BRAF-targeting Agent Vemurafenib in Melanoma Treatment by Inhibiting iNOS/hTERT Signaling and Cancer-Stem Cell Traits

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

Two Cases of Metastatic Malignant Melanoma

Japanese Journal of Neurosurgery
SurgeryNeurology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy